# The Business of Anti-Aging Science

## 

## João Pedro de Magalhães1,#,\* Michael Stevens1,#, Daniel Thornton1

## 1Integrative Genomics of Ageing Group, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool L7 8TX, United Kingdom

#Joint first authors

## \*Correspondence. Telephone: +44 151 7954517; E-mail: jp@senescence.info

## Abstract

Age-related conditions are the leading causes of death and healthcare costs. Reducing the rate of aging would have enormous medical and financial benefits. Myriads of genes and pathways are known to regulate aging in model organisms, fostering a new crop of anti-aging companies. Approaches range from drug discovery efforts to big data methods and direct-to-consumer strategies. Challenges and pitfalls to commercialization include reliance on findings from short-lived model organisms, poor biological understanding of aging and hurdles in performing clinical trials for aging. A large number of potential aging-associated interventions and targets exist, yet given long validation times, only a small fraction of them can be explored for clinical applications. If even one company succeeds, though, the impact will be huge.

**Keywords:** Biogerontology; geroscience; longevity; translational research; big pharma; pharmacology

## Treating multiple age-related diseases by retarding the aging process

The dream of fending off old age is as old as human civilization. Given the global aging of the population, however, developing interventions that preserve health in old age and postpone the onset of age-related diseases is more important than ever. In addition, we now know it is possible to retard aging in animal models. Various genetic, dietary and pharmacological interventions have been shown to increase lifespan, in some cases dramatically (10-fold is the current record), in short-lived model organisms like yeast, worms, flies, killifish, mice and rats [[1-3](#_ENREF_1)]. Importantly, life-extending interventions not only increase longevity but can retard the onset of age-related diseases, resulting in the extension of healthspan (i.e., the length of time one lives in good health). These breakthroughs in the biology of aging and its impact on health and disease, referred to by some as “geroscience”, have led to the promise that we will be able to delay or slow down human aging, resulting in unprecedented health benefits [[4](#_ENREF_4)].

Leading causes of death worldwide, and notably in industrialized countries, are age-related diseases like cardiovascular diseases, cancer and neurodegenerative diseases (Figure 1). Because of the strong relationship between the aging process and age-related diseases [[5](#_ENREF_5), [6](#_ENREF_6)], the benefits emerging from anti-aging science have enormous potential. Using a model of future health and spending in the USA, the effect of delayed aging resulting in 2.2 years additional life expectancy would yield $7 trillion in savings over 50 years; whereas addressing single pathologies such as cancer and heart disease would yield less, mostly due to competing risks [[7](#_ENREF_7)].

Aging can be defined as a progressive deterioration of physiological function, accompanied by an increase in vulnerability and mortality with age [[8](#_ENREF_8)]. Here, anti-aging based therapies are defined as those that delay the onset of multiple pathologies via core biological processes associated with age-related functional decline. While some therapies may be branded as single pathology for funding, business, or regulatory reasons, we include them nonetheless if they target aging-related processes or longevity-determining pathways and genes.

Given its huge potential financial benefits, anti-aging science has tremendous commercial opportunities. The anti-aging industry has struggled in the past in terms of reputation [[9](#_ENREF_9)], yet driven by more recent scientific breakthroughs it has been growing substantially with several young companies supported by world-leading brands like Google [[10](#_ENREF_10)]. In this piece, we first review companies and approaches in anti-aging biotech (Table 1). We then discuss some of the challenges and pitfalls in business development based on anti-aging science and lastly provide a vision for how the field may progress in the future.

## Anti-aging biotech companies and approaches

## *Pharmacological targeting of aging*

As with most diseases, traditional pharmacological approaches are the most straightforward and widely explored way to target aging. This topic has been reviewed [[1](#_ENREF_1), [4](#_ENREF_4), [11](#_ENREF_11), [12](#_ENREF_12)], and therefore will only be briefly discussed in (Box 1).

Notable examples of anti-aging drug discovery efforts include pharmacological manipulations of sirtuins, and sirtuin 1(*SIRT1*) in particular (targeted by resveratrol) and *TOR* (targeted by rapamycin), which are currently being explored [[1](#_ENREF_1)]. TOR inhibition by rapamycin results in increased lifespan from yeast to mammals [[1](#_ENREF_1), [13](#_ENREF_13)]. In a small but groundbreaking clinical trial by Novartis, rapamycin improved immune function in elderly volunteers [[14](#_ENREF_14)]. Because rapamycin has various side-effects, companies and labs are trying to develop safer analogues, known as “rapalogs”. One company focusing on the TOR pathway is Navitor Pharmaceuticals, which aims to treat diseases of aging through the selective regulation of the mTOR pathway. Another similar company focused on rapalogs, Mount Tam Biotechnologies, has worldwide licensing rights to the Buck Institute’s research assets related to auto-immune disease including the rapalog TAM-01 (http://www.buckinstitute.org/buck-news/buck-mt-tam-biosciences-target-lupus).

As for research on resveratrol and sirtuins, these were high-profile in 2008 when GlaxoSmithKline purchased sirtuin-focused biotech company Sirtris (based on the work of David Sinclair at Harvard Medical School) for $720 million. Enthusiasm in resveratrol and sirtuins as anti-aging compounds has arguably declined in more recent years. Briefly, results have been largely disappointing since then [[1](#_ENREF_1)] with resveratrol failing to extend lifespan in studies in mice [[15](#_ENREF_15)], among other controversies [[16](#_ENREF_16)]. GSK has closed Sirtris, although research on sirtuins and on new chemical entities that are thought to active sirtuins [[17](#_ENREF_17)] is still reportedly ongoing at GSK (<http://blogs.nature.com/news/2013/03/gsk-absorbs-controversial-longevity-company.html>). While Sirtris demonstrated that anti-aging biotech companies could rapidly grow in value and become a financial success for founders and early investors, its more recent problems might have hurt subsequent anti-aging science-based enterprises by discouraging investors and entrepreneurs.

Antioxidants have been historically a major focus of the field. However, currently, the idea that antioxidant pathways play a major role in aging is being challenged [[8](#_ENREF_8), [18](#_ENREF_18), [19](#_ENREF_19)], and epidemiological studies have by and large failed to support the supposed benefits of antioxidants [[20](#_ENREF_20)]. While many dietary supplements still focus on antioxidants, few companies in the field maintain such a focus. One exception is Antoxis which, founded in 2005, designs and synthesizes therapeutic antioxidants.

Telomeres, the protein bound structures at the ends of chromosomes, shorten with cell division and at least in some tissues with age [[8](#_ENREF_8), [21](#_ENREF_21)]. Although genetic manipulations of telomerase in mice have yielded conflicting results [[8](#_ENREF_8), [21](#_ENREF_21), [22](#_ENREF_22)], one study found that overexpression of telomerase in adult mice led to a 24% increase in median lifespan while not increasing the incidence of cancer [[23](#_ENREF_23), [24](#_ENREF_24)]. Therefore, the idea of activating telomerase as anti-aging remains a powerful one, even resulting in one self-experiment using gene therapy by BioViva [[25](#_ENREF_25)]. One notable company working on telomerase activation, Sierra Science, claims to have screened 250,000 compounds . Other companies focus on particular age-related diseases, such as Telocyte which is working on telomerase activation for Alzheimer’s disease.

Telomere shortening, as well as various stressors, can cause proliferating cells to stop dividing and enter a pro-inflammatory *senescent* state. There is evidence that senescent cells accumulate with age, at least in some tissues [[8](#_ENREF_8), [26](#_ENREF_26)]. In a landmark study, drug-induced clearance of p16Ink4a-positive cells (a marker of senescence) once a week from age one, extended the median lifespan in two normal strains of mice by 24-27%, though maximum lifespan was only (slightly) increased in one strain. Tumorigenesis and age-related deterioration in heart and kidney were delayed or slowed [[27](#_ENREF_27)]. As a consequence, Unity Biotechnology, a company founded by researchers at the Mayo Clinic involved in the abovementioned work as well as the Buck Institute, has raised $116 million from investors, including Amazon's founder, Jeff Bezos, to develop senolytic (i.e., an agent that destroys senescent cells) treatments. Continuing research by the co-founders has focused on senolytic agents, including killing of senescent fibroblasts with piperlongumine and ABT-263 [[28](#_ENREF_28)]. Interestingly, they have also acquired a patent related to a senescent cell antibody for imaging and delivery of therapeutic agents [[29](#_ENREF_29)].

Other companies focusing on senolytics include Oisin Biotechnologies, although according to their website they seem to be developing a genetically-targeted intervention to clear senescent cells, suggesting a different approach than Unity. Moreover, Everon Biosciences has shown that a significant portion of cells with p16Ink4a expression may actually be a subclass of macrophages, termed SAMs (senescent associated macrophages) [[30](#_ENREF_30)]. Following this discovery, Everon has announced that they will focus on these *SAMolytic* agents. Lastly, Siwa Therapeutics’ focuses on developing antibodies against senescent cell markers capable of identifying and removing senescent cells.

Given the multiple genes, processes and pathways associated with aging, there are many opportunities for developing pharmacological approaches against one's favorite target. For example, the idea that protein homeostasis is important during aging has led to the creation of Proteostasis Therapeutics, which aims to develop drugs that control the body's protein homeostasis which in turn could lead to therapies against genetic and degenerative disorders that include several age-related diseases. Also, Retrotope focuses on drug development for restoring mitochondrial health. Their first product candidate, RT001, is being clinically tested in Friedreich’s ataxia. While Cohbar has plans for phase 1 trials in 2018 for an analog of the mitochondrial MOTS-c peptide which was shown to prevent age-dependent inuslin resistence in mice [[31](#_ENREF_31)]. Lastly, while most efforts mentioned thus far are based on discoveries in model organisms, drugs targeting human longevity-associated genes are also promising [[1](#_ENREF_1)]. For example, Androcyte focuses on supercentenarians, individuals over 110 years of age, in the hope of identifying unique determinants of these human longevity outliers that may then be targeted pharmacologically.

## *Basic Biology and Big Data*

With a decidedly Silicon Valley-based confidence inspired by the successes of the high-tech industry spanning four decades, venture-capital funded big data approaches are being pursued in aging and longevity science. High profile players include Calico and Human Longevity Incorporated.

Started as one of Google's moonshot projects in 2013, Calico is attempting to harness big data to improve understanding of the basic biology that controls lifespan. Not much is known about how this will look in practice, however, they have formed an up to $1.5 billion partnership with AbbVie to develop drugs targeting diseases related to old age (https://news.abbvie.com/news/abbvie-and-calico-announce-novel-collaboration-to-accelerate-discovery-development-and-commercialization-new-therapies.htm).

Another high profile player is Human Longevity Incorporated (HLI) by Craig Venter. HLI is focused more directly on data than Calico, and aims to create the largest database of integrated high-throughput assays - genotypes, transcript and microbiome data, along with deep phenotypic data on patients in order to fully map genotype to phenotype to inform healthcare in general. Published efforts have focused on deep sequencing of human genomes [[32](#_ENREF_32)].

Other companies are using big data techniques to find new uses for already approved drugs [[12](#_ENREF_12)]. This is an attractive approach as pharmaceutical companies incur $1.8 billion capitalized costs to develop and get approval for drugs from scratch, while the safety of approved drugs is already known [[33](#_ENREF_33)]. While many companies do this, it forms a key component of some companies in longevity science. For one project, Insilico Medicine uses deep learning on multiple 'omic' data types to find new relationships between existing drugs and gene regulatory pathways effected in, or otherwise related to, aging-related diseases. Chronos Therapeutics, on the other hand, focuses on neurogenerative-specific age-related diseases. They patented the use of fujimycin, an already FDA-approved immunosuppressive drug for the treatment of eczema and organ transplants, to treat disorders related to cellular life-span which include many age-related diseases such as cardiovascular diseases, type II diabetes, Alzheimer’s, and osteoporosis by increasing cell lifespans through disruption of OBD1, a sirtuin inhibitor [[34](#_ENREF_34)]. While these approaches remain unproven in terms of translation, it is interesting to note that a network pharmacology approach was recently shown to be able to predict new life-extending compounds in worms [[35](#_ENREF_35)].

## *Direct-To-Consumer Approaches*

In addition to reasons for spending on basic-research in general, anti-aging science has unusual potential to benefit from market forces due to particularly favorable demographics. The median wealth of US families 62 or older is over $200k dollars, compared to $100k and $14k for middle-aged and young families, respectively. This may in part be responsible for the increase in investment in even non-traditional therapies and direct-to-consumer (DTC) products and services aimed at extending healthy lifespan.

One high-profile DTC company is Elysium Health which sells its Basis pill directly to consumers. Basis contains an NAD+ precursor, nicotinamide riboside, which declines with age and is required for sirtuin activity, and it also contains pterostilbene, which is similar to resveratrol. The systemic decline of NAD+ with age is a possible cause of age-associated changes in sirtuin activity in both the nucleus and mitochondria, with resulting age-associated dysfunction and pathologies [[36](#_ENREF_36)]. In addition to its role in redox reactions, NAD+ is an important substrate of several enzymes: sirtuins, ADP-ribose transferases, and PARPs, and CD38/CD157 (cADPR synthases) [[37](#_ENREF_37)].

Elysium have already concluded a pre-registered 2 month randomized, double blind phase 1 trial for Basis using 120 healthy 60-80 year olds. While results have yet to be published, a company press release claims that participant’s blood NAD+ levels were increased by 40% for the duration of the second month. However, the release did not mention the results of health measures such as lipid profile, physiological performance, or sleep quality (https://www.elysiumhealth.com/clinical-trial-press-release).

Another notable product, Juvenon, by Juvenon, uses α-lipoic acid and acetyl-l-carnitine as main ingredients. Feeding rats acetyl-l-carnitine and α-lipoic acid leads to a decline in oxidative stress and DNA damage as well improved movement and memory [[38](#_ENREF_38), [39](#_ENREF_39)].

Caloric restriction (CR) is the most studied and most consistent intervention that increases both health- and life-span. While a CR diet is too harsh for most people, intermittent fasting (IF) has been proposed as a less restrictive alternative (Box 2). Based on this premise, L-Nutra was created to develop and market proprietary fasting-mimetic meals designed to provide the beneficial effects of IF. Their first formulation, ProLon, consists of five days of meals to be taken every 1 to 6 months. In a registered, randomized 38 person clinical trial, ProLon was shown to reduce levels of weight, abdominal fat, and maintain healthy levels of blood glucose, C-reactive protein (CRP), and insulin-like growth factor 1 (IGF1) [[40](#_ENREF_40)].

Using long-lived "Methuselah" flies, Genescient uses genetic and gene expression network analysis to discover genetic determinates of this long lived strain. Their goal is to translate these findings into human targets by developing nutrigenomic-based therapies for chronic age-related diseases. Their proprietary combination of four herbal extracts had mixed results in extending lifespan in flies with greater effect on stressed flies [[41](#_ENREF_41)].

## *Young Blood*

Perhaps most uniquely surprising, therapies are now being tested based on research into the effects of parabiosis (Box 3). A Stanford University spin-out, Alkahest, with some of the main parabiosis researchers on board, was formed to take advantage of this research and test the effect of young plasma as a treatment for Alzheimer's. Grifols, the largest plasma-based manufacturer worldwide, has invested $38M in Alkahest with an additional $13M to develop and sell Alkehest’s plasma based products (http://www.grifols.com/en/web/international/view-news/-/new/grifols-to-make-a-major-equity-investment-in-alkahest). Additionally, young human blood has been shown to revitalize brain function in old mice [[42](#_ENREF_42)].

One further company, Ambrosia, was established to run a clinical trial on the anti-aging benefits of young blood in relatively healthy people [[25](#_ENREF_25), [43](#_ENREF_43)]. Controversially, however, the company is planning to charge participants $8000, making this a pay-to-participate trial that has raised ethical concerns [[43](#_ENREF_43)].

## *Stem Cells and Regenerative Medicine*

A number of companies have also been focusing on stem cells and regenerative medicine. Given the multiple uses of stem cells, the applications in regenerative medicine extend far beyond aging conditions and diseases. Nonetheless, a few companies have focused in particular on age-related conditions. Examples include BioTime which aims to develop embryonic/iPS stem cell therapies and regenerative medicine, Centagen that aims to activate adult stem cells and RepliCel Life Sciences which focuses on regenerative medicine to treat injured tendons, pattern baldness and skin damaged by sun and age.

## Challenges in developing human anti-aging therapies

## A growing number of companies are now focusing on anti-aging science (Table 1). In a way this is surprising given that the first high-profile anti-aging company, Sirtris, while a success as an early investment, has thus far failed to live up to its anti-aging expectations. Modern advances, abundant aging-related targets and an aging population can arguably be driving the current crop of anti-aging biotechs. But how realistic is it that these will succeed? In a sense, there are few assumptions that we can be confident of. At present we can state that: 1) aging is a complex process; 2) although there are a number of theories of aging with vocal advocates, there is no consensus among scientists regarding the underlying causes of aging; 3) aging can be manipulated in short-lived model systems by genetic, dietary and pharmacological intervention. But that leaves many open questions (highlighted in the Outstanding Questions Box) and so the uncertainty concerning human anti-aging approaches remains very high.

*Humans are not huge worms or big mice*

Although findings from short-lived model organisms, in particular in terms of the *plasticity of aging*, have been a major breakthrough of the field, the degree to which those are relevant to humans is unknown. Human homologs of genes associated with aging in model organisms have been in some cases associated with human longevity, but these are rare (Figure 2) and thus our understanding of the genetic basis of human longevity remains largely unknown [[44](#_ENREF_44)]. For example, one recent large-scale study found only two loci significantly associated with human longevity, and failed to validate previous findings like the association of *IGF1R* with longevity [[45](#_ENREF_45)]. Therefore, it is perfectly plausible that most findings from short-lived model organisms will not be relevant to human beings [[44](#_ENREF_44)]. Briefly, the pathways necessary to extend lifespan in model systems may not only be often irrelevant to the comparatively long-lived human species, but to make matters worse, studies in model systems are mostly performed on genetically homogeneous laboratory strains that may not be representative of human populations [[44](#_ENREF_44)]. Besides, our understanding of aging manipulations is far superior in short-lived models like yeast and worms rather than rodents [[1](#_ENREF_1), [2](#_ENREF_2), [46](#_ENREF_46)], due to the ease of performing large-scale screens (Figure 2).

Given the above concerns, a major open question is how effective anti-aging interventions can be in human beings. Even if they have benefits, how do these compare to mundane lifestyle choices like going to the gym? Likewise, while some anti-aging therapies might have benefits, they may not be beneficial for everyone. On the bright side, there are various efforts to develop alternative model systems, including dogs [[47](#_ENREF_47)] and primates [[48](#_ENREF_48)], though of course the limitation is that studies in such animals take much longer and are more expensive than in rodents.

## *So many targets, so little time*

According to the GenAge database, we now know of >2,000 genes that modulate longevity in model organisms [[2](#_ENREF_2)], and the DrugAge database lists >400 compounds that can increase longevity in model organisms [[46](#_ENREF_46)]. Indeed, most aging-related genes and pathways have not been targeted pharmacologically yet [[46](#_ENREF_46)]. Given the volumes of data generated in the life sciences, various approaches in computational and systems biology have been developed to help identify and rank new candidates, identify regulatory genes and gather biological insights [[35](#_ENREF_35), [49-51](#_ENREF_49)], as reviewed in [[52](#_ENREF_52)]. Such approaches are imperative, as is the integration of different expertise in developing and prioritizing targets, drugs and therapies for testing. In spite of these advances, our capacity to identify interventions that will succeed in clinical trials remains poor.

One crucial limitation in biotech is the long time it takes for clinical validation and for obtaining regulatory approval [[53](#_ENREF_53)]. Taking several years, clinical trials are long, expensive operations. In aging this is even more of an issue because aging is, compared to traditional diseases, a relatively long process and we still lack accepted aging biomarkers that can be used as endpoints. In addition, the field of life sciences is still immature in that our knowledge of human biology is still very incomplete [[54](#_ENREF_54)]. As such, while the number of targets has increased dramatically thanks to advances in technologies like genomics, our capacity to validate those targets in a clinical setting has not substantially improved [[53](#_ENREF_53)]. In other words, the success rates of clinical trials remains very low [[55](#_ENREF_55)], and pharmaceutical R&D efficiency has even declined [[56](#_ENREF_56)], in spite of what is generally agreed as substantial technological progress in recent decades. Therefore, biotech is a risky business that requires long-term involvement, and anti-aging biotech even more so.

## *Clinical trials for aging and rejuvenation*

Because of the time it takes for aging to develop, clinical trials for aging per se are not realistic at the moment. One effort led by Nir Barzilai, however, is trying to perform the first clinical trial for aging, using metformin, which would be an important proof of principle [[57](#_ENREF_57)]. Even if successful, there are many practical challenges in performing clinical trials for aging, including how long it will take and how much it will cost [[1](#_ENREF_1), [58](#_ENREF_58), [59](#_ENREF_59)]. As abovementioned, we also still lack suitable biomarkers of aging, which is a major impediment [[12](#_ENREF_12)]. Recent advances in developing epigenetic biomarkers of aging, an “epigenetic clock”, offer promise [[60](#_ENREF_60)], but it is still unclear whether these are suitable for clinical trials.

An additional concern in anti-aging interventions is whether these are suitable for old and frail individuals and/or long-term administration. Drugs like metformin already being clinically used may in particular be suitable for targeting aging, and recent discussions have explored how to develop a preclinical drug development pipeline in anti-aging [[58](#_ENREF_58), [59](#_ENREF_59)]. In addition, while commercialization of medical interventions is dominated by small molecule pharmaceuticals, investment stemming from advances in anti-aging science now include young blood therapies, senescent cell ablation, and DTC diets and nutraceuticals (Table 1).

One important development in anti-aging therapies focuses on rejuvenation. Some anti-aging interventions like resveratrol and many longevity drugs promise to slow down aging, which for clinical testing entails a variety of problems described above. On the other hand, interventions like senolytic drugs and young blood promise rejuvenation which is less challenging from a validation perspective, and therefore much more attractive for commercial exploitation. Therefore, developing interventions that reverse at least some aspect of aging is a more powerful translational path than trying to slow down aging.

## *Future prospects and concluding remarks*

Of the 4000 private and 600 public biotechnology companies worldwide only a few percent have shown increasing profitability. Historically, only one out of 5000 discovery-stage drug candidates obtain approval and only a third of those recoup their R&D costs [[61](#_ENREF_61)]. Besides, as above mentioned, the success rate of clinical trials is not improving, even though we have more information, data and potential targets than ever before. Given the various constraints on studying aging, including the reliance on short-lived model organisms, long validation times and poor biological understanding, it would be very surprising if most companies described here are active a mere 5-10 years from now. Likewise, most companies in the anti-aging biotech sector are startups, and thus riskier. From an investor’s perspective this means that investors in anti-aging biotech are expecting to lose money but hoping to win big.

Omics approaches are imperative, as is a multidisciplinary outlook, but while these have augmented the search space, attrition rates remain very high. Perhaps surprisingly, in spite of the so far failure of Sirtris, which would be expected to hurt the industry, anti-aging biotech is more vibrant than ever. Clearly, even such high-profile failure has not dissuaded investors, including many tech billionaires. As such, no doubt new technologies will be developed and new targets discovered in the coming years and decades, possibly opening new avenues for the commercialization of aging into other directions. The promise of fending off old age remains more powerful than ever and the financial gains for any company delivering on that promise will continue to be extremely attractive. Anti-aging biotech can then be seen as an extreme reflection of the biotech sector: risky, most likely to fail, but if one company is successful the outcomes are monumental.

**Acknowledgements**

Work in our lab is supported by the Wellcome Trust (104978/Z/14/Z), the Leverhulme Trust (RPG-2016-015), LongeCity and the Methuselah Foundation.

**Conflict of interest**

JPM and MS are advisors to Androcyte. JPM has also performed consultancy work for Genescient.

## Table 1:

### Anti-aging Biotech Companies (also see: http://whoswho.senescence.info/companies.php)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Name** | **Funding/Capital/Size** | **Founded** | **URL** | **Therapeutic approach** |
| **Pharmacological targeting** | | | |  |
| Antoxis | $2.5M | 2005 | antoxis.com | Anti-oxidants |
| Androcyte |  |  | supercentenarianstudy.com | Genetic study of supercentenarians |
| Sierra Science | Research LLC, Marketing partner Defytime | 1999 | sierrasci.com / defytime.jp | Telomerase activating compounds |
| Prana Biotechnology | $20M, public 2002 | 1997 | pranabio.com | Neurodegenerative disease therapies. PBT2 in phase 2b trials. |
| Biotie | $152M, acquired by Acorda Therapeutics 2016 | 1998 | biotie.com | Neurodgenerative disease therapies. SYN-115 in phase 3 trials |
| Navitor Pharmaceuticals | $57M | 2014 | navitorpharma.com | Rapalogs |
| Cohbar | $9.2M, public 2015 | 2009 | cohbar.com | Mitochondrial-based therapies. Planned clinical trial for MOTS-c analog. |
| Telocyte | Angels | 2015 | telocyte.com | Telomerase activation for Alzheimers |
| Unity | $116M | 2009 | unitybiotechnology.com | Senolytic agents |
| Oisin Bio | < $5M, Development/ Pre-clinical | 2014 | oisinbio.com | Gene therapy based senescent cell clearance |
| Everon Biosciences |  | 2009 | everonbio.com | SAMolytic agents |
| Siwa Therapeutics |  |  | siwatherapeutics.com | Senescent cell antibodies |
| Proteostasis Therapeutics | $108M, public 2016 | 2007 | proteostasis.com | Drug-based control of protein homostasis |
| Retrotope | $15M | 2006 | retrotope.com | Drug-based mitochrondrial restoration. RT001 in phase 1/2 trials for Friedreich’s ataxia |
| Mount Tam Biotechnologies | Pre-clinical, public 2015 | 2014 | mounttambiotech.com | Rapalogs. TAM-01 in pre-clinical trials for systemic lupus erythematosus |
| resTORbio | $15M, clinical subsidiary of Puretech Health | 2017 | restorbio.com | Develop immunosenescence drugs. mTORC1 inhibitor, RTB101, in phase 2 trial. |
|  |  |  |  |  |
| **Big Data** | | | |  |
| Calico |  | 2013 | calicolabs.com | Develop drugs based on the biology that controls lifespan |
| HLI | $300M | 2013 | humanlongevity.com | Integrate large omic data sets to find patterns in age-related diseases |
| Insilico Medicine | VC funded C-corp start-up | 2014 | insilicomedicine.com | Identify existing drugs effecting age-related gene pathways |
| Chronos Therapeutics | $12M | 2009 | chronostherapeutics.com | Repurpose drugs for neurogenerative disease, patented use of fujimycin |
| Gero | $6M, Research |  | gero.com | Gene network analysis to identify anti-aging targets, worm study in progress. Also has activity-based wellness predictor phone app. |
|  |  |  |  |  |
| **Direct-To-Consumer** | | | |  |
| Elysium Health | $20M | 2014 | elysiumhealth.com | Neutricals. trial-tested, NAD+ precursor, Basis |
| Juvenon |  | 1999 | juvenon.com | Rat-tested oxidative stress reducer, Juvenon |
| L-Nutra | $10M round B | 2009 | l-nutra.com | Trial-tested, fasting mimetic diet, ProLon |
| Genescient | $500K | 2006 | genescient.com | Nutriceuticals based on genetic analysis of long-lived flies |
|  |  |  |  |  |
| **Young Blood** | | | |  |
| Alkahest | $54M | 2014 | alkahest.com | Working with Grifols to develop plasma-based therapies |
| Ambrosia |  |  | ambrosiaplasma.com | For profit clinical trial to study blood-based therapy |
|  |  |  |  |  |
| **Stem Cell / Regenerative** | | | |  |
| BioTime | $76M, public 1992 |  | biotimeinc.com | Develop cell therapies |
| Centagen |  |  | centagen.com | Develop activators of adult stem cells |
| RepliCel Life Sciences | $3M, Development | 2006 | replicel.com | Develop regeneration-based therapies, phase 1 clinical trials for achilles tendinosis and age-related skin damage |
| BioViva | Crowdfunded | 2015 | bioviva-science.com | Gene-therapy to induce telomerase |
|  |  |  |  |  |
| **Biomarkers** | | | |  |
| Genox - subsidiary of NIKKEN SEIL |  | 1991 | genox.com |  |
| Interleukin Genetics | $65M  (public 2003) | 1997 | ilgenetics.com |  |

**Text Box 1: A plethora of potential drug targets**

The multitude of genes, processes and pathways modulating aging in short-lived model organisms provide a plethora of potential targets for drug discovery [[1](#_ENREF_1)]. Hundreds of genes modulating aging and/or longevity have been identified in model organisms [[2](#_ENREF_2)], most of which can be grouped into common pathways and processes like insulin/insulin-like signaling, autophagy, oxidative phosphorylation and TOR signaling [[6](#_ENREF_6)]. There is also evidence that life-extending pathways tend to be evolutionarily conserved [[62](#_ENREF_62)]. For instance, disruption of the insulin/insulin-like growth factor 1 (IGF1) pathway has been shown to extend lifespan in yeast, worms, flies, and mice, and *IGF1R* mutations have been associated with human longevity [[3](#_ENREF_3)]. As such, evolutionarily conserved life-extending genes and pathways are important targets for drug discovery [[1](#_ENREF_1)].

**Text Box 2: Intermittent fasting is less restrictive than caloric restriction.**

Intermittent fasting (IF) - where for example, calories are reduced 40%, two days a week - has been argued by some experts to have the same range of benefits as chronic CR [[63](#_ENREF_63)]. In a further refinement, a low calorie/low protein diet eaten for four days every two weeks, without effecting total long term caloric intake, appears to have similar effects. Middle-aged mice showed improvements in a broad set of age-related phenotypes including: reduced visceral fat, fewer incidence of some cancers, fewer tissues with inflammation, reduced immunosenescence, improvement of some types of memory, and an 11% increase in median lifespan [[40](#_ENREF_40)]. A similar diet, taken five days a month for three months, showed reduced fasting glucose, lower circulation IGF1, fat loss, reduced C-reactive protein for those with elevated cardiovascular disease risk in a 38 person pre-registered pilot trial [[40](#_ENREF_40)]. Subsequently, a similar pilot trial of 100 healthy participants, reported a reduction in markers for aging, diabetes, cancer, and cardiovascular disease [[64](#_ENREF_64)].

**Text Box 3: Anti-aging effects of young blood**

In biology, parabiosis is the joining of two animals' circulatory systems. Historically it was noticed that connected healthy animals could extend the lifespan of treated animals [[65](#_ENREF_65)], though such effects have not been subsequently validated. In a series of studies starting in the 1950's, it was observed that the older of the pair had better longevity and tissue function [[65](#_ENREF_65)] whereas young mice exposed to old plasma showed a decrease [[66](#_ENREF_66)]. Further, aged mice given young plasma showed improvement in age-related decline in hippocampal-dependent learning and memory [[67](#_ENREF_67)]. However, 10-12 month CBA/Ca female mice (a strain with normal longevity) injected weekly with young plasma did not show increased lifespan [[68](#_ENREF_68)]. Most recently, using a blood exchange device to exchange blood between young and old mice once, old mice had improved hepatogenesis and response to muscle injury while young animals showed no difference and injury response worsened hepatogenesis. For every other test -including physical performance and hippocampal neurogenesis – while young mice worsened, old mice showed no difference [[69](#_ENREF_69)].

**Figure legends**

Figure 1: Between the years 2010 and 2015 in the US, an average of 2,577,202 deaths per annum from an average yearly population size of 315,109,368 were recorded (0.818%). The chart shows the top 8 broad causes of death, with the major contributors being age-related and chronic diseases such as cancer, diseases of the heart, stroke and Alzheimer’s disease. The categories in the pie chart were grouped based on ICD codes as follows: Heart disease (I00-I09, I11, I13, I20-I51); Cancer (C00-C97); Chronic lower respiratory diseases (J40-J47); Stroke (I60-I69); Unintentional injuries (V01-X59,Y85-Y86); Alzheimer's disease (G30); Diabetes (E10-E14); Influenza and pneumonia (J09-J18). Data from the Centers for Disease Control and Prevention, CDC Wide-ranging ONline Data for Epidemiologic Research (CDC WONDER) - https://wonder.cdc.gov/ucd-icd10.html

Figure 2: Genetics of aging from model organisms to humans. The numbers below each organism represent the number of aging and/or longevity-associated genes for each organism in the GenAge database [[2](#_ENREF_2)]; for humans, only genes directly associated with human aging and/or longevity according to GenAge are included. The area of the circles is proportional to the number of genes.

## References

1 de Magalhaes, J.P.*, et al.* (2012) Genome-environment interactions that modulate aging: powerful targets for drug discovery. *Pharmacological reviews* 64, 88-101

2 Tacutu, R.*, et al.* (2013) Human Ageing Genomic Resources: integrated databases and tools for the biology and genetics of ageing. *Nucleic acids research* 41, D1027-1033

3 Kenyon, C.J. (2010) The genetics of ageing. *Nature* 464, 504-512

4 Kennedy, B.K. and Pennypacker, J.K. (2014) Drugs that modulate aging: the promising yet difficult path ahead. *Translational research : the journal of laboratory and clinical medicine* 163, 456-465

5 Kennedy, B.K.*, et al.* (2014) Geroscience: linking aging to chronic disease. *Cell* 159, 709-713

6 Fernandes, M.*, et al.* (2016) Systematic analysis of the gerontome reveals links between aging and age-related diseases. *Human molecular genetics* 25, 4804-4818

7 Goldman, D.P.*, et al.* (2013) Substantial health and economic returns from delayed aging may warrant a new focus for medical research. *Health Affairs (Project Hope)* 32, 1698-1705

8 de Magalhaes, J.P. (2011) The biology of ageing: A primer. In *An Introduction to Gerontology* (Stuart-Hamilton, I., ed), pp. 21-47, Cambridge University Press

9 Olshansky, S.J.*, et al.* (2002) No truth to the fountain of youth. *Sci Am* 286, 92-95

10 Scott, C.T. and DeFrancesco, L. (2015) Selling long life. *Nature biotechnology* 33, 31-40

11 Vaiserman, A.M.*, et al.* (2016) Anti-aging pharmacology: Promises and pitfalls. *Ageing research reviews* 31, 9-35

12 Mallikarjun, V. and Swift, J. (2016) Therapeutic Manipulation of Ageing: Repurposing Old Dogs and Discovering New Tricks. *EBioMedicine* 14, 24-31

13 Harrison, D.E.*, et al.* (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature* 460, 392-395

14 Mannick, J.B.*, et al.* (2014) mTOR inhibition improves immune function in the elderly. *Science translational medicine* 6, 268ra179

15 Miller, R.A.*, et al.* (2011) Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. *The journals of gerontology. Series A, Biological sciences and medical sciences* 66, 191-201

16 Schmidt, C. (2010) GSK/Sirtris compounds dogged by assay artifacts. *Nature biotechnology* 28, 185-186

17 Hubbard, B.P. and Sinclair, D.A. (2014) Small molecule SIRT1 activators for the treatment of aging and age-related diseases. *Trends in pharmacological sciences* 35, 146-154

18 de Magalhaes, J.P. and Church, G.M. (2006) Cells discover fire: employing reactive oxygen species in development and consequences for aging. *Exp Gerontol* 41, 1-10

19 Lapointe, J. and Hekimi, S. (2010) When a theory of aging ages badly. *Cellular and molecular life sciences : CMLS* 67, 1-8

20 Bjelakovic, G.*, et al.* (2008) Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. *Cochrane Database Syst Rev*, CD007176

21 de Magalhaes, J.P. (2013) How ageing processes influence cancer. *Nature reviews. Cancer* 13, 357-365

22 de Magalhaes, J.P. and Toussaint, O. (2004) Telomeres and telomerase: a modern fountain of youth? *Rejuvenation Res* 7, 126-133

23 Bernardes de Jesus, B.*, et al.* (2012) Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. *EMBO molecular medicine* 4, 691-704

24 Bär, C. and Blasco, M.A. (2016) Telomeres and telomerase as therapeutic targets to prevent and treat age-related diseases. *F1000Research* 5

25 Hamzelou, J. (2017) Time to stop getting old. *New Scientist* 233, 22-23

26 de Magalhaes, J.P. (2004) From cells to ageing: a review of models and mechanisms of cellular senescence and their impact on human ageing. *Exp Cell Res* 300, 1-10

27 Baker, D.J.*, et al.* (2016) Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. *Nature* 530, 184-189

28 Wang, Y.*, et al.* (2016) Discovery of piperlongumine as a potential novel lead for the development of senolytic agents. *Aging* 8, 2915-2926

29 Squires, S.C. CENEXYS, INC. COMPOSITIONS AND METHODS FOR DETECTING OR ELIMINATING SENESCENT CELLS TO DIAGNOSE OR TREAT DISEASE, US20150151001.

30 Hall, B.M.*, et al.* (2016) Aging of mice is associated with p16(Ink4a)- and β-galactosidase-positive macrophage accumulation that can be induced in young mice by senescent cells. *Aging* 8, 1294-1315

31 Lee, C.*, et al.* (2015) The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. *Cell Metab* 21, 443-454

32 Telenti, A.*, et al.* (2016) Deep sequencing of 10,000 human genomes. *Proceedings of the National Academy of Sciences of the United States of America* 113, 11901-11906

33 Paul, S.M.*, et al.* (2010) How to improve R&D productivity: the pharmaceutical industry's grand challenge. *Nature reviews. Drug discovery* 9, 203-214

34 Mellor, E.J.O. et al. Chronos Therapeutics Limited. METHOD OF TREATING AGE RELATED DISORDERS, US20120136046.

35 Calvert, S.*, et al.* (2016) A network pharmacology approach reveals new candidate caloric restriction mimetics in C. elegans. *Aging Cell* 15, 256-266

36 Imai, S.-i. and Guarente, L. (2014) NAD+ and sirtuins in aging and disease. *Trends in Cell Biology* 24, 464-471

37 Verdin, E. (2015) NAD⁺ in aging, metabolism, and neurodegeneration. *Science (New York, N.Y.)* 350, 1208-1213

38 Hagen, T.M.*, et al.* (2002) Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. *Proceedings of the National Academy of Sciences of the United States of America* 99, 1870-1875

39 Liu, J.*, et al.* (2002) Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. *Proceedings of the National Academy of Sciences of the United States of America* 99, 2356-2361

40 Brandhorst, S.*, et al.* (2015) A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. *Cell Metabolism* 22, 86-99

41 Villeponteau, B.*, et al.* (2015) Herbal supplement extends life span under some environmental conditions and boosts stress resistance. *PLoS One* 10, e0119068

42 Castellano, J.M.*, et al.* (2017) Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. *Nature*

43 Kaiser, J. (2016) BIOMEDICINE. Antiaging trial using young blood stirs concerns. *Science* 353, 527-528

44 de Magalhaes, J.P. (2014) Why genes extending lifespan in model organisms have not been consistently associated with human longevity and what it means to translation research. *Cell Cycle* 13, 2671-2673

45 Deelen, J.*, et al.* (2014) Genome-wide association meta-analysis of human longevity identifies a novel locus conferring survival beyond 90 years of age. *Human molecular genetics*

46 Barardo, D.*, et al.* (2017) The DrugAge database of aging-related drugs. *Aging Cell*

47 Check Hayden, E. (2014) Pet dogs set to test anti-ageing drug. *Nature* 514, 546

48 Fischer, K.E. and Austad, S.N. (2011) The development of small primate models for aging research. *ILAR journal* 52, 78-88

49 Cevenini, E.*, et al.* (2010) Systems biology and longevity: an emerging approach to identify innovative anti-aging targets and strategies. *Current pharmaceutical design* 16, 802-813

50 Wuttke, D.*, et al.* (2012) Dissecting the gene network of dietary restriction to identify evolutionarily conserved pathways and new functional genes. *PLoS genetics* 8, e1002834

51 Plank, M.*, et al.* (2012) A meta-analysis of caloric restriction gene expression profiles to infer common signatures and regulatory mechanisms. *Molecular bioSystems* 8, 1339-1349

52 de Magalhaes, J.P. and Tacutu, R. (2016) Integrative Genomics of Aging. In *Handbook of the Biology of Aging, 8th edition* (Kaeberlein, M. and Martin, G.M., eds), pp. 263-285, Academic Press

53 Pisano, G.P. (2006) *Science business: The promise, the reality, and the future of biotech*. Harvard Business Press

54 de Magalhaes, J.P. (2014) The scientific quest for lasting youth: prospects for curing aging. *Rejuvenation Res* 17, 458-467

55 Hay, M.*, et al.* (2014) Clinical development success rates for investigational drugs. *Nature biotechnology* 32, 40-51

56 Scannell, J.W.*, et al.* (2012) Diagnosing the decline in pharmaceutical R&D efficiency. *Nature reviews. Drug discovery* 11, 191-200

57 Barzilai, N.*, et al.* (2016) Metformin as a Tool to Target Aging. *Cell Metab* 23, 1060-1065

58 Newman, J.C.*, et al.* (2016) Strategies and Challenges in Clinical Trials Targeting Human Aging. *The journals of gerontology. Series A, Biological sciences and medical sciences* 71, 1424-1434

59 Burd, C.E.*, et al.* (2016) Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms. *The journals of gerontology. Series A, Biological sciences and medical sciences* 71, 1388-1394

60 Horvath, S.*, et al.* (2016) An epigenetic clock analysis of race/ethnicity, sex, and coronary heart disease. *Genome biology* 17, 171

61 Kolchinsky, P. (2004) The Entrepreneur’s guide to a Biotech Startup. *4th. Edition*

62 Smith, E.D.*, et al.* (2008) Quantitative evidence for conserved longevity pathways between divergent eukaryotic species. *Genome research* 18, 564-570

63 Mattson, M.P.*, et al.* (2016) Impact of intermittent fasting on health and disease processes. *Ageing research reviews*

64 Wei, M.*, et al.* (2017) Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. *Science translational medicine* 9

65 Conboy, M.J.*, et al.* (2013) Heterochronic parabiosis: historical perspective and methodological considerations for studies of aging and longevity. *Aging Cell* 12, 525-530

66 Villeda, S.A.*, et al.* (2011) The aging systemic milieu negatively regulates neurogenesis and cognitive function. *Nature* 477, 90-94

67 Villeda, S.A.*, et al.* (2014) Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. *Nature Medicine* 20, 659-663

68 Shytikov, D.*, et al.* (2014) Aged Mice Repeatedly Injected with Plasma from Young Mice: A Survival Study. *BioResearch Open Access* 3, 226-232

69 Rebo, J.*, et al.* (2016) A single heterochronic blood exchange reveals rapid inhibition of multiple tissues by old blood. *Nature Communications* 7, 13363